Pfizer is looking to newer products and acquisitions to offset a declining Covid business.
1don MSN
Pfizer's 6.5% dividend yield looked too good to be true -- but management just silenced the skeptics
Is Pfizer a yield trap? No way.
By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer reported higher-than-expected sales and profit on Tuesday and ...
Pfizer’s $2.3 billion bet on Trillium Therapeutics doesn’t look like it will ever pay out, with the Big Pharma abandoning the ...
Pfizer is also demonstrating that its commercial portfolio can flourish beyond the historically mammoth sales of its COVID-19 ...
By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth ...
Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...
Despite the continued decline of Pfizer's COVID-19 products, shares stayed stable on Tuesday morning after the New York ...
Pharma giant is working hard to offset its post-Covid hangover but faces a patent cliff on many top-selling medicines ...
Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.
Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in ...
Shares of Pfizer are down 50% from their 2021 high, and the yield is an alluring 6.4%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results